A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB007839 Following Multiple Oral Doses in Patients With Solid Tumors
Interventional
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Identify a maximum tolerable dose as measured through adverse event reporting, ECGs and laboratory assessments
Baseline through study completion
No
William V Williams, MD
Study Director
Incyte Corporation
United States: Food and Drug Administration
INCB 7839-201
NCT00820560
January 2005
January 2009
Name | Location |
---|---|
Philadelphia, Pennsylvania 19104 | |
Nashville, Tennessee 37203-1632 | |
Denver, Colorado | |
Baltimore, Maryland 21287 |